Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-07-28
CRISPR Therapeutics AG
Gene-editing biotech developing one-time medicines across hemoglobinopathies, cardiometabolic disease, autoimmune disease, oncology, and diabetes, with shared economics in CASGEVY and a broader wholly owned pipeline.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Editing, Unproven Platform Conversion
The approved asset establishes trust and the balance sheet buys time, but the real rerating still depends on converting platform breadth into at least one more credible commercial franchise. That makes the setup attractive but still proof-gated.

Analysis

Thesis
CRISPR Therapeutics already cleared the hardest trust gate with the first approved CRISPR therapy; if CASGEVY keeps converting starts into treated patients and just one owned branch such as CTX310 or zugo-cel becomes commercially credible, the stock can rerate from cash-backed optionality to a multi-franchise gene-medicine platform by 2031.
Last Economy Alignment
AI should help this company design, learn, and iterate faster, but value capture is still gated by clinical proof, manufacturing, reimbursement, and regulation rather than cheap cognition alone.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
This is a realistic asymmetric setup, not a moonshot. The approved asset gives commercial proof, the balance sheet buys time, and several owned programs can create the rerating. I do not need every branch to work; I need CASGEVY to become a steadier cash engine and one owned franchise to look commercially repeatable. That supports a multi-year re-rating, but the clinical and operational gates still argue against a more extreme bucket today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not immediate liquidity. CRISPR needs CASGEVY to become a repeatable commercial cash flow source and at least one owned program to show durable human efficacy, clean enough safety, and a workable delivery model; otherwise the stock can remain a partner-dependent approved asset plus a portfolio the market values mostly as scientific optionality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.38
They control real gene-editing know-how, some manufacturing, and a growing clinical data loop, so AI should help them design and improve medicines faster. But they still have to pass regulators, work through specialized treatment sites, and share their flagship launch with Vertex, so the flywheel is real but not frictionless.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$84.70
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case